XBiotech (XBIT) Competitors $2.75 -0.07 (-2.48%) Closing price 04:00 PM EasternExtended Trading$2.74 0.00 (-0.18%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XBIT vs. VIGL, AQST, OLMA, RCKT, FULC, ABEO, ALDX, ATXS, BNTC, and ADCTShould you be buying XBiotech stock or one of its competitors? The main competitors of XBiotech include Vigil Neuroscience (VIGL), Aquestive Therapeutics (AQST), Olema Pharmaceuticals (OLMA), Rocket Pharmaceuticals (RCKT), Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), Aldeyra Therapeutics (ALDX), Astria Therapeutics (ATXS), Benitec Biopharma (BNTC), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. XBiotech vs. Its Competitors Vigil Neuroscience Aquestive Therapeutics Olema Pharmaceuticals Rocket Pharmaceuticals Fulcrum Therapeutics Abeona Therapeutics Aldeyra Therapeutics Astria Therapeutics Benitec Biopharma ADC Therapeutics XBiotech (NASDAQ:XBIT) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends. Which has more volatility & risk, XBIT or VIGL? XBiotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 3.33, suggesting that its stock price is 233% more volatile than the S&P 500. Do analysts recommend XBIT or VIGL? Vigil Neuroscience has a consensus price target of $10.80, suggesting a potential upside of 34.16%. Given Vigil Neuroscience's stronger consensus rating and higher probable upside, analysts clearly believe Vigil Neuroscience is more favorable than XBiotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vigil Neuroscience 0 Sell rating(s) 10 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation & earnings, XBIT or VIGL? XBiotech has higher revenue and earnings than Vigil Neuroscience. Vigil Neuroscience is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXBiotech$4.01M20.91-$38.53M-$0.92-2.99Vigil NeuroscienceN/AN/A-$84.26M-$2.05-3.93 Is XBIT or VIGL more profitable? XBiotech's return on equity of -15.60% beat Vigil Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets XBiotechN/A -15.60% -14.64% Vigil Neuroscience N/A -111.70%-74.67% Do insiders & institutionals hold more shares of XBIT or VIGL? 55.7% of XBiotech shares are owned by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 18.0% of Vigil Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to XBIT or VIGL? In the previous week, XBiotech had 4 more articles in the media than Vigil Neuroscience. MarketBeat recorded 4 mentions for XBiotech and 0 mentions for Vigil Neuroscience. XBiotech's average media sentiment score of 1.45 beat Vigil Neuroscience's score of 0.00 indicating that XBiotech is being referred to more favorably in the media. Company Overall Sentiment XBiotech Positive Vigil Neuroscience Neutral SummaryXBiotech beats Vigil Neuroscience on 9 of the 13 factors compared between the two stocks. Get XBiotech News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIT vs. The Competition Export to ExcelMetricXBiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.97M$3.20B$5.86B$10.15BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-2.9921.1774.5225.93Price / Sales20.91463.28536.78122.58Price / CashN/A46.6837.5660.44Price / Book0.469.6112.166.29Net Income-$38.53M-$53.29M$3.28B$270.77M7 Day Performance-5.82%0.29%0.98%3.36%1 Month Performance-7.41%8.91%7.20%6.41%1 Year Performance-59.68%13.14%63.06%28.26% XBiotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBITXBiotech1.9215 of 5 stars$2.75-2.5%N/A-56.4%$85.97M$4.01M-2.99100Positive NewsShort Interest ↓VIGLVigil NeuroscienceN/A$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340AQSTAquestive Therapeutics2.251 of 5 stars$3.77-1.6%$10.14+169.0%+0.0%$375.96M$57.56M-5.39160OLMAOlema Pharmaceuticals2.8454 of 5 stars$5.46-1.1%$24.00+339.6%-35.2%$374.74MN/A-2.7670News CoveragePositive NewsAnalyst UpgradeRCKTRocket Pharmaceuticals4.7919 of 5 stars$3.28-2.1%$16.73+410.2%-82.8%$353.92MN/A-1.31240Short Interest ↑FULCFulcrum Therapeutics2.6486 of 5 stars$6.48-2.6%$7.57+16.8%-21.0%$350.51M$80M-5.31100News CoveragePositive NewsShort Interest ↓ABEOAbeona Therapeutics4.2837 of 5 stars$6.83-0.7%$19.50+185.5%+20.8%$350.23M$3.50M9.7690Positive NewsALDXAldeyra Therapeutics2.1699 of 5 stars$5.84-0.3%$9.50+62.7%-10.2%$349.79MN/A-6.8710Positive NewsATXSAstria Therapeutics3.0217 of 5 stars$6.18-5.4%$29.00+369.3%-26.2%$348.77MN/A-3.0730BNTCBenitec Biopharma1.7435 of 5 stars$13.24+1.6%$26.00+96.4%+65.6%$347.56M$80K-8.7720Positive NewsADCTADC Therapeutics3.0558 of 5 stars$3.08-5.4%$7.75+152.0%+12.9%$345.37M$70.84M-1.96310News CoverageShort Interest ↓ Related Companies and Tools Related Companies VIGL Competitors AQST Competitors OLMA Competitors RCKT Competitors FULC Competitors ABEO Competitors ALDX Competitors ATXS Competitors BNTC Competitors ADCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XBIT) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
